Evaluating M3/M21 as a Tumor Marker in Ovarian Cancer
Author Information
Author(s): C Tempfer, L Hefler, G Haeusler, G Sliutz, E Hanzal, A Reinthaller, CH Kainz
Primary Institution: University of Vienna, Medical School
Hypothesis
The study aims to evaluate the clinical usefulness of the serum evaluation of M3/M21 in patients with ovarian cancer.
Conclusion
M3/M21 serum levels are elevated in ovarian cancer patients and may be useful for monitoring and predicting outcomes.
Supporting Evidence
- M3/M21 showed a sensitivity of 78% and specificity of 85%.
- Elevated M3/M21 serum levels before therapy were associated with poor overall survival.
- Lead time effects were observed in 19 patients, ranging from 2 to 8 months.
Takeaway
Doctors looked at a blood test called M3/M21 to see if it can help find ovarian cancer early and predict how well patients will do.
Methodology
This retrospective study included serological examinations of 75 patients with ovarian cancer, evaluating M3/M21 serum levels before surgery and during follow-up.
Potential Biases
Potential bias due to the retrospective nature and the specific patient population studied.
Limitations
The study is retrospective and may not account for all variables affecting outcomes.
Participant Demographics
Median age was 55.6 years, with patients across FIGO stages Ia to III.
Statistical Information
P-Value
0.02
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website